Osteoporosis Drugs Market by Drug Class (Bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), Parathyroid Hormone Therapy, Calcitonin, Rank Ligand Inhibitors, and Others) and Route of Administration (Oral, Injectable, and Others): Global Opportunity Analysis and Industry Forecast, 2019–2026

March 2020 | 230 pages | ID: OA88660FEEA9EN
Allied Market Research

Abstracts

The global osteoporosis drugs market accounted for $7,657 million in 2018, and is expected to reach $10,479 million by 2026, registering a CAGR of 3.9% from 2019 to 2026.

Osteoporosis drugs are defined as therapeutic agents which are utilized in the treatment of osteoporosis. Furthermore, osteoporosis is a serious medical condition which is associated with the presence of fragile bones. In addition, these fragile bones are dense and prone to fractures. Moreover, the condition is caused due to the over production of hormone parathyroid and leads to limited mobility in patients suffering from the condition. Thus, this medical condition requires early diagnosis and medical treatment which includes the administration of various drugs such as bisphosphonates selective estrogen inhibitors modulator (SERM), parathyroid hormone therapy, calcitonin, rank ligand inhibitors and others. In addition, these drugs are administered through different routes in the body such as oral route of administration, intravenous route of administration and others.

The major factor that contributes to the growth of osteoporosis drugs market include rise in prevalence of osteoporosis. Furthermore, other factors that boost osteoporosis drugs market growth include surge in geriatric population across the globe and rise in adoption of sedentary lifestyle worldwide. However, side effects of osteoporosis drugs, and stringent regulatory environment and the time-consuming drug approval process hampers the growth of osteoporosis drugs market. Conversely, high growth potential in developing economies is expected to offer lucrative opportunities during the forecast period.

The osteoporosis drugs market size is studied on the basis of drug class, route of administration, and region to provide a detailed assessment of the market. On the basis of drug class, it is segmented into bisphosphonates, selective estrogen inhibitors modulator (SERM), parathyroid hormone therapy, calcitonin, rank ligand inhibitors, and others. By route of administration, it is bifurcated into oral, injectable and others. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS

• This report entails a detailed quantitative analysis along with the current global influenza treatmentmarket trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessments.
• The market size and estimations are based on a comprehensive analysis of key developments in the industry.
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Key Market Segments

• By Drug Class
• Bisphosphonates
• Selective Estrogen Inhibitors Modulator (SERM)
• Parathyroid Hormone Therapy
• Calcitonin
• Rank Ligand Inhibitors
• Others
• By Route of administration
• Oral
• Injectable
• Others
• By Region
• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• France
• UK
• Italy
• Rest of Europe
• Asia-Pacific
• Japan
• China
• India
• Rest of Asia-Pacific
• LAMEA
• Brazil
• Saudi Arabia
• South Africa
• Rest of LAMEA
• List of key players profiled in the report:
• Amgen Inc.
• F. Hoffmann-La Roche AG
• Radius Health, Inc.
• Merck & Co. Inc.
• Novartis International AG (Sandoz)
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd

LIST OF OTHER PLAYERS IN THE VALUE CHAIN(These players are not profiled in the report. The same will be included on request)

• GlaxoSmithKline plc
• Novo Nordisk A/S

Contents

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. Key market segments
1.4. Research methodology
  1.4.1. Secondary research
  1.4.2. Primary research
  1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Top player positioning
  3.2.1. Top investment pockets
3.3. Porter's five force analysis
3.4. Market dynamics
  3.4.1. Drivers
    3.4.1.1. Rise in prevalence of osteoporosis
    3.4.1.2. Rapid increase in aging population
    3.4.1.3. Adoption of sedentary lifestyle
  3.4.2. Restraints
    3.4.2.1. Side effects of osteoporosis drugs
    3.4.2.2. Stringent regulatory drug approval process
  3.4.3. Opportunity
    3.4.3.1. High growth prospects in emerging markets
  3.4.4. Impact analyses

CHAPTER 4: OSTEOPOROSIS DRUGS MARKET, BY DRUG CLASS

4.1. Overview
  4.1.1. Market size and forecast
4.2. Bisphosphonates
  4.2.1. Key market trends, growth factors, and opportunities
  4.2.2. Market size and forecast, by region
  4.2.3. Market analysis, by country
4.3. Selective estrogen inhibitors modulator
  4.3.1. Key market trends, growth factors, and opportunities
  4.3.2. Market size and forecast, by region
  4.3.3. Market analysis, by country
4.4. Parathyroid hormone therapy
  4.4.1. Key market trends, growth factors, and opportunities
  4.4.2. Market size and forecast, by region
  4.4.3. Market analysis, by country
4.5. Calcitonin
  4.5.1. Key market trends, growth factors, and opportunities
  4.5.2. Market size and forecast, by region
  4.5.3. Market analysis, by country
4.6. Rank ligand inhibitors
  4.6.1. Key market trends, growth factors, and opportunities
  4.6.2. Market size and forecast, by region
  4.6.3. Market analysis, by country
4.7. Others
  4.7.1. Key market trends, growth factors, and opportunities
  4.7.2. Market size and forecast, by region
  4.7.3. Market analysis, by country

CHAPTER 5: OSTEOPOROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION

5.1. Overview
  5.1.1. Market size and forecast
5.2. Oral
  5.2.1. Market size and forecast, by region
  5.2.2. Market analysis, by country
5.3. Injectable
  5.3.1. Market size and forecast, by region
  5.3.2. Market analysis, by country
5.4. Others
  5.4.1. Market size and forecast, by region
  5.4.2. Market analysis, by country

CHAPTER 6: OSTEOPOROSIS DRUGS MARKET, BY REGION

6.1. Overview
  6.1.1. Market size and forecast
6.2. North America
  6.2.1. Key market trends and opportunities
  6.2.2. North America osteoporosis drugs market, by country
    6.2.2.1. U.S.
      6.2.2.1.1. U.S. market size and forecast, by drug class
      6.2.2.1.2. U.S. market size and forecast, by route of administration
    6.2.2.2. Canada
      6.2.2.2.1. Canada market size and forecast, by drug class
      6.2.2.2.2. Canada market size and forecast, by route of administration
    6.2.2.3. Mexico
      6.2.2.3.1. Mexico market size and forecast, by drug class
      6.2.2.3.2. Mexico market size and forecast, by route of administration
  6.2.3. North America market size and forecast, by drug class
  6.2.4. North America market size and forecast, by route of administration
6.3. Europe
  6.3.1. Key market trends and opportunities
  6.3.2. Europe osteoporosis drugs market, by country
    6.3.2.1. Germany
      6.3.2.1.1. Germany market size and forecast, by drug class
      6.3.2.1.2. Germany market size and forecast, by route of administration
    6.3.2.2. France
      6.3.2.2.1. France market size and forecast, by drug class
      6.3.2.2.2. France market size and forecast, by route of administration
    6.3.2.3. UK
      6.3.2.3.1. UK market size and forecast, by drug class
      6.3.2.3.2. UK market size and forecast, by route of administration
    6.3.2.4. Italy
      6.3.2.4.1. Italy market size and forecast, by drug class
      6.3.2.4.2. Italy market size and forecast, by route of administration
    6.3.2.5. Spain
      6.3.2.5.1. Spain market size and forecast, by drug class
      6.3.2.5.2. Spain market size and forecast, by route of administration
    6.3.2.6. Rest of Europe
      6.3.2.6.1. Rest of Europe market size and forecast, by drug class
      6.3.2.6.2. Rest of Europe market size and forecast, by route of administration
  6.3.3. Europe market size and forecast, by drug class
  6.3.4. Europe market size and forecast, by route of administration
6.4. Asia-Pacific
  6.4.1. Key market trends and opportunities
  6.4.2. Asia-Pacific osteoporosis drugs market, by country
    6.4.2.1. Japan
      6.4.2.1.1. Japan market size and forecast, by drug class
      6.4.2.1.2. Japan market size and forecast, by route of administration
    6.4.2.2. China
      6.4.2.2.1. China market size and forecast, by drug class
      6.4.2.2.2. China market size and forecast, by route of administration
    6.4.2.3. Australia
      6.4.2.3.1. Australia market size and forecast, by drug class
      6.4.2.3.2. Australia market size and forecast, by route of administration
    6.4.2.4. India
      6.4.2.4.1. India market size and forecast, by drug class
      6.4.2.4.2. India market size and forecast, by route of administration
    6.4.2.5. South Korea
      6.4.2.5.1. South Korea market size and forecast, by drug class
      6.4.2.5.2. South Korea market size and forecast, by route of administration
    6.4.2.6. Rest of Asia-Pacific
      6.4.2.6.1. Rest of Asia-Pacific market size and forecast, by drug class
      6.4.2.6.2. Rest of Asia-Pacific market size and forecast, by route of administration
  6.4.3. Asia-Pacific market size and forecast, by drug class
  6.4.4. Asia-Pacific market size and forecast, by route of administration
6.5. LAMEA
  6.5.1. Key market trends and opportunities
  6.5.2. LAMEA osteoporosis drugs market, by country
    6.5.2.1. Brazil
      6.5.2.1.1. Brazil market size and forecast, by drug class
      6.5.2.1.2. Brazil market size and forecast, by route of administration
    6.5.2.2. Saudi Arabia
      6.5.2.2.1. Saudi Arabia market size and forecast, by drug class
      6.5.2.2.2. Saudi Arabia market size and forecast, by route of administration
    6.5.2.3. South Africa
      6.5.2.3.1. South Africa market size and forecast, by drug class
      6.5.2.3.2. South Africa market size and forecast, by route of administration
    6.5.2.4. Rest of LAMEA
      6.5.2.4.1. Rest of LAMEA market size and forecast, by drug class
      6.5.2.4.2. Rest of LAMEA market size and forecast, by route of administration
  6.5.3. LAMEA market size and forecast, by drug class
  6.5.4. LAMEA market size and forecast, by route of administration

CHAPTER 7: COMPANY PROFILES

7.1. Amgen Inc.
  7.1.1. Company overview
  7.1.2. Company snapshot
  7.1.3. Operating business segments
  7.1.4. Product portfolio
  7.1.5. Business performance
  7.1.6. Key strategic moves and developments
7.2. Eli Lilly and Company
  7.2.1. Company overview
  7.2.2. Company snapshot
  7.2.3. Operating business segments
  7.2.4. Product portfolio
  7.2.5. Business performance
7.3. F. HOFFMANN-LA ROCHE LTD.
  7.3.1. Company overview
  7.3.2. Company snapshot
  7.3.3. Operating business segments
  7.3.4. Product portfolio
  7.3.5. Business performance
7.4. Radius Health, Inc.
  7.4.1. Company overview
  7.4.2. Company snapshot
  7.4.3. Operating business segments
  7.4.4. Product portfolio
  7.4.5. Business performance
7.5. Merck & Co. Inc.
  7.5.1. Company overview
  7.5.2. Company snapshot
  7.5.3. Operating business segments
  7.5.4. Product portfolio
  7.5.5. Business performance
7.6. Novartis International AG (Sandoz)
  7.6.1. Company overview
  7.6.2. Company snapshot
  7.6.3. Operating business segments
  7.6.4. Product portfolio
  7.6.5. Business performance
7.7. Pfizer Inc.
  7.7.1. Company overview
  7.7.2. Company snapshot
  7.7.3. Operating business segments
  7.7.4. Product portfolio
  7.7.5. Business performance
7.8. Sun Pharmaceutical Industries Ltd.
  7.8.1. Company overview
  7.8.2. Company snapshot
  7.8.3. Operating business segments
  7.8.4. Product portfolio
  7.8.5. Business performance
7.9. Takeda Pharmaceutical Company Limited
  7.9.1. Company overview
  7.9.2. Company snapshot
  7.9.3. Operating business segments
  7.9.4. Product portfolio
  7.9.5. Business performance
7.10. Teva Pharmaceutical Industries Ltd.
  7.10.1. Company overview
  7.10.2. Company snapshot
  7.10.3. Operating business segments
  7.10.4. Product portfolio
  7.10.5. Business performance
  7.10.6. Key strategic moves and developments

List Of Tables

LIST OF TABLES

TABLE 01. GLOBAL OSTEOPOROSIS DRUGS MARKET, BY DRUG CLASS, 2018–2026 ($MILLION)
TABLE 02. BISPHOSPHONATES MARKET , BY REGION, 2018–2026 ($MILLION)
TABLE 03. SELECTIVE ESTROGEN INHIBITORS MODULATOR MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04. PARATHYROID HORMONE THERAPY MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 05. CALCITONIN MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 06. RANK LIGAND INHIBITORS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 07. OTHER OSTEOPOROSIS DRUGS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 08. OSTEOPOROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 09. ORAL OSTEOPOROSIS DRUGS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 10. INJECTABLE OSTEOPOROSIS DRUGS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 11. OSTEOPOROSIS DRUGS MARKET FOR OTHER ROUTE OF ADMINISTRATION, BY REGION, 2018–2026 ($MILLION)
TABLE 12. OSTEOPOROSIS DRUGS MARKET REVENUE, BY REGION, 2018–2026 ($MILLION)
TABLE 13. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 14. U.S. OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 15. U.S. OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 16. CANADA OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 17. CANADA INFLUENZA TREATMENT OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2019–2026 ($MILLION)
TABLE 18. MEXICO OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 19. MEXICO OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2019–2026 ($MILLION)
TABLE 20. NORTH AMERICA OSTEOPOROSIS DRUGS REVENUE, BY DRUG CLASS, 2019–2026($MILLION)
TABLE 21. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026($MILLION)
TABLE 22. EUROPE OSTEOPOROSIS DRUGS MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 23. GERMANY OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 24. GERMANY OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 25. FRANCE OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 26. FRANCE OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2019–2026 ($MILLION)
TABLE 27. UK OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 28. UK OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2019–2026 ($MILLION)
TABLE 29. ITALY OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 30. ITALY OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2019–2026 ($MILLION)
TABLE 31. SPAIN OSTEOPOROSIS DRUGS REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 32. SPAIN OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2019–2026 ($MILLION)
TABLE 33. REST OF EUROPE OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 34. REST OF EUROPE OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2019–2026 ($MILLION)
TABLE 35. EUROPE OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026($MILLION)
TABLE 36. EUROPE OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026($MILLION)
TABLE 37. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 38. JAPAN OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 39. JAPAN OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 40. CHINA OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 41. CHINA OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2019–2026 ($MILLION)
TABLE 42. AUSTRALIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 43. AUSTRALIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2019–2026 ($MILLION)
TABLE 44. INDIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 45. INDIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2019–2026 ($MILLION)
TABLE 46. SOUTH KOREA OSTEOPOROSIS DRUGS REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 47. SOUTH KOREA OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2019–2026 ($MILLION)
TABLE 48. REST OF ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 49. REST OF ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2019–2026 ($MILLION)
TABLE 50. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026($MILLION)
TABLE 51. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026($MILLION)
TABLE 52. LAMEA OSTEOPOROSIS DRUGS MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 53. BRAZIL OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 54. BRAZIL OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 55. SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 56. SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2019–2026 ($MILLION)
TABLE 57. SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 58. SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2019–2026 ($MILLION)
TABLE 59. REST OF LAMEA OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 60. REST OF LAMEA OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2019–2026 ($MILLION)
TABLE 61. LAMEA OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026($MILLION)
TABLE 62. LAMEA OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026($MILLION)
TABLE 63. AMGEN: COMPANY SNAPSHOT
TABLE 64. AMGEN: PRODUCT SEGMENT
TABLE 65. AMGEN: PRODUCT PORTFOLIO
TABLE 66. LILLY: COMPANY SNAPSHOT
TABLE 67. LILLY: OPERATING SEGMENTS
TABLE 68. LILLY: PRODUCT PORTFOLIO
TABLE 69. ROCHE: COMPANY SNAPSHOT
TABLE 70. ROCHE: OPERATING SEGMENTS
TABLE 71. ROCHE: PRODUCT PORTFOLIO
TABLE 72. RADIUS: COMPANY SNAPSHOT
TABLE 73. RADIUS: PRODUCT PORTFOLIO
TABLE 74. MERCK: COMPANY SNAPSHOT
TABLE 75. MERCK: OPERATING SEGMENTS
TABLE 76. MERCK: PRODUCT PORTFOLIO
TABLE 77. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 78. NOVARTIS: OPERATING SEGMENTS
TABLE 79. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 80. PFIZER: COMPANY SNAPSHOT
TABLE 81. PFIZER: OPERATING SEGMENTS
TABLE 82. PFIZER: PRODUCT PORTFOLIO
TABLE 83. SUN PHARMA: COMPANY SNAPSHOT
TABLE 84. SUN PHARMA: OPERATING SEGMENTS
TABLE 85. SUN PHARMA: PRODUCT PORTFOLIO
TABLE 86. TAKEDA: COMPANY SNAPSHOT
TABLE 87. TAKEDA: OPERATING SEGMENTS
TABLE 88. TAKEDA: PRODUCT PORTFOLIO
TABLE 89. TEVA: COMPANY SNAPSHOT
TABLE 90. TEVA: OPERATING SEGMENTS
TABLE 91. TEVA: PRODUCT PORTFOLIO

List Of Figures

LIST OF FIGURES

FIGURE 01. GLOBAL OSTEOPOROSIS DRUGS MARKET SEGMENTATION
FIGURE 02. TOP PLAYER POSITIONING, 2018
FIGURE 03. TOP INVESTMENT POCKETS
FIGURE 04. HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTION
FIGURE 07. HIGH INTENSITY OF RIVALRY
FIGURE 08. LOW THREAT OF NEW ENTRANTS
FIGURE 09. IMPACT ANALYSES
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF BISPHOSPHONATES MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF SELECTIVE ESTROGEN INHIBITORS MODULATOR MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PARATHYROID HORMONE THERAPY MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF CALCITONIN MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF RANK LIGAND INHIBITORS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF OTHER OSTEOPOROSIS DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ORAL OSTEOPOROSIS DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF INJECTABLE OSTEOPOROSIS DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF OSTEOPOROSIS DRUGS MARKET FOR OTHER ROUTE OF ADMINISTRATION, BY COUNTRY, 2018 & 2026 (%)
FIGURE 19. U.S. OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 20. CANADA OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 21. MEXICO OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 22. COMPARISON OF MALE GERIATRIC POPULATION IN EUROPEAN COUNTRIES, 2017 (MILLION)
FIGURE 23. GERMANY OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 24. FRANCE OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 25. UK OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 26. ITALY OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 27. SPAIN OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 28. REST OF EUROPE OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 29. JAPAN OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 30. CHINA OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 31. AUSTRALIA OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 32. INDIA OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 33. SOUTH KOREA OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 34. REST OF ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 35. BRAZIL OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 36. SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 37. SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 38. REST OF LAMEA OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 39. AMGEN: NET SALES, 2016–2018 ($MILLION)
FIGURE 40. AMGEN: REVENUE SHARE BY REGION, 2018(%)
FIGURE 41. LILLY: NET SALES, 2016–2018 ($MILLION)
FIGURE 42. LILLY: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 43. LILLY: REVENUE SHARE BY REGION, 2018(%)
FIGURE 44. ROCHE: NET SALES, 2016–2018 ($MILLION)
FIGURE 45. ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 46. ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 47. RADIUS: NET SALES, 2016–2018 ($MILLION)
FIGURE 48. MERCK: NET SALES, 2016–2018 ($MILLION)
FIGURE 49. MERCK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 50. MERCK: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 51. NOVARTIS: NET SALES, 2016–2018 ($MILLION)
FIGURE 52. NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 53. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 54. PFIZER: REVENUE, 2016–2018 ($MILLION)
FIGURE 55. PFIZER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 56. PFIZER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 57. SUN PHARMA: NET SALES, 2016–2018 ($MILLION)
FIGURE 58. SUN PHARMA: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 59. TAKEDA: NET SALES, 2016–2018 ($MILLION)
FIGURE 60. TAKEDA: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 61. TAKEDA: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 62. TEVA: NET SALES, 2016–2018 ($MILLION)
FIGURE 63. TEVA: REVENUE SHARE BY GEOGRAPHY, 2018 (%)